The next generation of researchers are continuously inspiring and fueling NHF’s renewed focus on research. Dr. Olubusola (Bosula) Oluwole is one of the first-ever recipients of the new Jeanne Marie Lusher (JML) Diversity Fellowship.…
*/
Gene Therapy 101 for Patients and Families
Speakers:
Len Valentino, MD
President and Chief Executive Officer
National Bleeding Disorders Foundation
Jim Munn, MS, BSN, RN-BC
Program Nurse Coordinator
Michigan Medicine…
We invite you to join the quarterly board of directors meeting for the National Hemophilia Foundation on May 24th starting at 7:00 pm ET. This meeting will discuss NHF business operations and decisions and is…
NHF’s Third Collaborative Learning Exchange will be on -
Managing Complex Cases with Novel Non-Factor Therapies
This live virtual workshop will provide prescribers with an opportunity for interactive…
The long-term goal of my work is to improve treatment options for patients with hemophilia and other heritable bleeding disorders. The goal of my current research is to understand the impact of factor VIII
deficiency on brain structure and function…
The U.S. Food and Drug Administration (FDA) has accepted CSL Behring’s Biologics License Application (BLA) for priority review of etranacogene dezaparvovec, an investigational gene therapy for hemophilia B.
Etranacogene dezaparvovec, also known…
Individuals and families in the bleeding disorders community and those who experience other chronic rare conditions have not typically been engaged in patient reported registries or in clinical studies during the initial study design phase. The more…